Description overdue on 09.03.2012

Plasma-drug . Drug action aimed at restoring blood flow in the capillaries of small caliber, increasing the stability of the suspension of blood provision detoxifying effect , Reduction and prevention Aggregation   blood cells, normalization of venous and blood circulation , Decreasing blood viscosity . Reopoliglyukin stimulates diuresis   by osmotic mechanism by glomerular filtration, creating a high oncotic pressure   in the primary urine and obstruction of the process reabsorption   water in the tubules. Thanks to this mechanism of action of accelerating the elimination of toxins, toxic substances, degradation products of metabolism. As a result, pronounced volume effect improves hemodynamics and faster washout of metabolic products of their organs and tissues, which simultaneously leads to an increase in urine output accelerated detoxification of the human body. The drug is quickly and briefly increases blood volume, which increases venous blood return to the heart. Patients with vascular insufficiency increased blood pressure, central venous pressure, minute volume of blood. Have an average molecular weight of the drug. Rapid introduction leads to an increase in plasma half in comparison with the volume of injected solution. Reopoliglyukin is non-pyrogenic Nontoxic. Due to its effect decreases and prevents the aggregation of erythrocytes, which positively acts on microcirculation. The drug prevents the formation of blood clots after injuries and surgical interventions, reducing platelet adhesiveness, increases the solubility of blood clots due to structural changes in the structure of fibrin. With the introduction of the drug to 15 ml / kg, there is a marked deviation of the bleeding time. Reopolgiglyukin available as a solution for intravenous infusion.

Indications:

Reopoliglyukin appointed to fill the volume of circulating blood, improved capillary blood flow fat embolism , Paralytic ileus, in toxic shock, post-operative shock, cardiogenic, hemorrhagic, burns and traumatic shocks. The drug allows to replace the volume of plasma in the blood loss in pediatric patients. The drug is prescribed to improve the venous and arterial circulation in thrombophlebitis , Thrombosis, Raynaud's disease , Occlusive disease, acute stroke . nutritional diseases . In order prescribed for detoxification reopologlyukin pancreatitis , Peritonitis, nutritional diseases, crush syndrome, extensive purulent and necrotic lesions of the soft tissues in ulcerative, necrotizing enterocolitis "Syndrome inclusion." In the preoperative period prescribed for Reopolglyukin hemodilution . With the help of the drug therapeutic plasmapheresis is performed to replace the removed plasma volume. The drug is added to the perfusion solution during open heart surgery in extracorporeal circulation apparatus for preventing thrombus formation on heart valves, vascular grafts. The drug is effective in impaired microcirculation in idiopathic or traumatic hearing loss. The drug is prescribed for diseases of the optic nerve, retinal disease, inflammatory processes in the cornea pathology choroid.

Contraindications:

Reopoliglyukin contraindicated in thrombocytopenia , Bleeding, intolerance of components of the drug, renal pathology system ( anuria , Oliguria). With abundant mucopurulent offices, skin maceration century electrophoresis is strictly contraindicated.

Side effect:

Nausea, febrile syndrome, chills, fever, anaphylactoid reactions , Collapse, drop in blood pressure, skin rashes and other allergic reactions. The drug can cause the development of acute renal failure and provoke bleeding.

Mode of application:

Given hematocrit, blood pressure, heart rate, patient's condition and the individual characteristics of the dosage was calculated. Reopolglyukin injected permissible drip, jet and jet-drip. Be sure before drug administration with the exception of urgent, life-threatening conditions, conduct skin test : Injection site treated with an alcohol in the middle part on the inner surface of the forearm, then intradermally administered 0, 05 ml, should form a twist of lemon peel. With the development of nausea, dizziness, the appearance of redness at the injection site, formation of papules talk about the patient's intolerance of the drug. Be sure to hold bioassay : After the first five drops reopoliglyukina infusion was stopped for three minutes, then adding another 30 drops again stop .  In the absence of an infusion reaction continued for the calculated scheme .  Register bioassay results in the history of the disease is required .  Patients with impaired capillary blood flow injection of the drug Reopoliglyukin held jet-drip, drop 0, 5-1, 5 liters to complete stabilization of hemodynamic parameters at the level of life support .  In severe cases, the amount of injected solution was increased to two liters .  When the amount of the drug to children shocks calculated according to the scheme: 5-10 ml / kg, may be increased to 15 ml / kg .  The amount is not recommended to lower the hematocrit below 25% .  With plastic surgery, cardiovascular operations Reopoliglyukin administered immediately before surgical treatment for an hour at a dose of 10 ml / kg .  After surgery the drug is administered intravenously for one hour .  When surgery with cardiopulmonary bypass drug is added to the blood by the scheme: 10-20 ml / kg in order to fill the pump oxygenator .  For detoxification drug is administered intravenously at a dose of 500-1250 ml for 1-1, 5:00 .

Special instructions:

Reopolglyukin can be administered with crystalloid solutions for the maintenance and replacement of electrolyte, fluid balance . Such injections should be carried out after serious surgical interventions, dehydrated patients. In the case of simultaneous administration anticoagulants   it is strongly recommended reduction of dosage. Reopolglyukin able to increase diuresis. By reducing diuresis, excretion syrupy, viscous urine talk about dehydration and intravenous colloids   for the maintenance and replenishment   water and electrolyte balance . When furosemide is administered oliguria and brine. Patients with impaired renal function filtration systems limit the introduction of sodium chloride. Dextrans prevent blood type, envelop the surface of red blood cells, which requires the use of washed red blood cells.